ADVERTISEMENT
Log in here to read the desired article.
ADVERTISEMENT
This author has not written his bio yet.
But we are proud to say that Thomas Gabrielczyk contributed 2131 entries already.
Synbio specialist Sherlock Biosciences and next-generation lateral flow testing expert Mologic Ltd have joined forces to develop a no-instrument rapid testing platform detecting virtually every infectious pathogen in low resource settings.
German researchers have shown that a protein protects against the development of liver fibrosis by shutting down inflammatory signalling in liver stellate cells of the liver.
Cell reprogramming specialist bit bio has expanded its management with renowned experts in the field.
Swiss biotech company BioVersys AG has received a €8m grant by US-based non-profit organisation CARB-X to develop novel anti-virulence antibiotics to treat severe bacterial infections.
A team of Japanese and German researchers has found the protein that helps activate the inflammasome following viral invasion.
Researchers at University Lyon have found a potential repurposing application of two market-approved rotavirus vaccines.
Swiss Polyphor AG and researchers from the University of Zurich have presented the mechanism of action of a new class of antibiotics.
SMEs active in antibiotic development are trying to adapt to the uncertain AMR business. Meanwhile, the European IMI AMR accelerator kicked off.
Zealand Pharma A/S has acquired Encycle Therapeutics Inc, including a peptide therapeutics platform and library.
Antibiotic developers struggle with uncertain market conditions, weak reimbursement schemes and low turnover once a drug is approved. Experts are trying to figure out the best way to balance push and pull incentives.